EP0149578B1 - Nouveaux dérivés de la xanthine, leur procédé de préparation et les compositions pharmaceutiques les renfermant - Google Patents

Nouveaux dérivés de la xanthine, leur procédé de préparation et les compositions pharmaceutiques les renfermant Download PDF

Info

Publication number
EP0149578B1
EP0149578B1 EP85400072A EP85400072A EP0149578B1 EP 0149578 B1 EP0149578 B1 EP 0149578B1 EP 85400072 A EP85400072 A EP 85400072A EP 85400072 A EP85400072 A EP 85400072A EP 0149578 B1 EP0149578 B1 EP 0149578B1
Authority
EP
European Patent Office
Prior art keywords
xanthine
general formula
propyl
carbon atoms
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP85400072A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0149578A2 (fr
EP0149578A3 (en
Inventor
Gilbert Regnier
Claude Guillonneau
Jacques Duhault
François Roman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADIR SARL
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Priority to AT85400072T priority Critical patent/ATE40368T1/de
Publication of EP0149578A2 publication Critical patent/EP0149578A2/fr
Publication of EP0149578A3 publication Critical patent/EP0149578A3/fr
Application granted granted Critical
Publication of EP0149578B1 publication Critical patent/EP0149578B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine

Definitions

  • the subject of the present invention is new xanthine derivatives, their preparation methods and the pharmaceutical compositions containing them.
  • the prior art is represented by xanthines substituted in position -1 or -7 by an amino-alkyl chain, and having coronarodilator (BSM 5086) anti-myocardial (EP 68544) or antiallergic (EP 21103) activities.
  • BSM 5086 coronarodilator
  • EP 68544 anti-myocardial
  • EP 21103 antiallergic
  • the xanthines of the present invention substituted in the 8-position, unexpectedly possess antispasmodic and psychostimulatory properties, and crossing the hemeno-meningeal barrier, find their therapeutic application as anti-migraine or psychotropic.
  • the subject of the present invention is the process for the preparation of derivatives of general formula 1 characterized in that:
  • the condensation is preferably carried out in a solvent chosen from alcohols containing up to 4 carbon atoms, such as for example methanol, ethanol, propanol or butanol. It is advantageous to operate at a temperature of between 80 and 110 ° C., in the presence of an acceptor of the hydracid formed during the reaction.
  • This acceptor may for example be a tertiary amine such as triethylamine or an excess of the amino derivative of formula III used for the reaction.
  • These new derivatives (1) can be purified by physical methods such as crystallization, chromatography or chemicals such as the formation of addition salts with acids and the decomposition of these salts by alkaline agents.
  • the derivatives of general formula I and their physiologically tolerable salts have interesting pharmacological and therapeutic properties, in particular anti-migraine and central psychotonic properties.
  • the derivatives studied exhibit a spasmolytic activity demonstrated in vitro on isolated preparation of guinea-pig taenia coli (FERRARI M. and CARPENEDOF; Arch. Lnt. Pharmacol (1968) 174, 223). These substances inhibit the contraction that accompanies the membrane depolarization caused by K + ions and the contraction caused by extracellular Ca ++.
  • the average effective doses (ED 50 ) vary according to the products from 2.10- 5 M to 8.10- 4 M.
  • these compounds inhibit the enzymatic activity of the phosphodiesterase responsible for the degradation of the 3'.5'-adenosine monophosphate cyclic.
  • the intracellular accumulation of this substance can also explain the relaxation of smooth muscle fibers.
  • the enzyme source is a rat brain homogenate
  • the mean inhibitory concentration (IC 50) is between 1,5 - 10- 5 M and 1.10- 4 M (Nair KG, Biochem (1966), 5, 150).
  • theophylline has an LC 50 of 1.2.10-4M.
  • the present invention also relates to pharmaceutical compositions containing as active ingredient a derivative of general formula 1, or one of its physiologically tolerable salts, mixed or associated with a suitable pharmaceutical excipient.
  • compositions thus obtained are advantageously presented in various forms such as, for example, tablets, dragees, capsules, glossettes or pharmaceutical preparations suitable for sublingual administration, suppositories, injectable or drinkable solutions as well as in forms suitable for administration by aerosol.
  • the starting trimethyl-1,3,7 (3-piperazino-propyl) -8 xanthine was prepared by debenzylation with hydrogen in the presence of palladium carbon, under a pressure of about 3.10 6 Pa, of trimethyl-1, 3,7 [(4-benzyl piperazino) -3 propyl] -8 xanthine, itself prepared as mentioned in the French patent application published under No. 2,531,085 February 3, 1984.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP85400072A 1984-01-17 1985-01-16 Nouveaux dérivés de la xanthine, leur procédé de préparation et les compositions pharmaceutiques les renfermant Expired EP0149578B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT85400072T ATE40368T1 (de) 1984-01-17 1985-01-16 Xanthin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8400659A FR2558162B1 (fr) 1984-01-17 1984-01-17 Nouveaux derives de la xanthine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
FR8400659 1984-01-17

Publications (3)

Publication Number Publication Date
EP0149578A2 EP0149578A2 (fr) 1985-07-24
EP0149578A3 EP0149578A3 (en) 1985-09-18
EP0149578B1 true EP0149578B1 (fr) 1989-01-25

Family

ID=9300191

Family Applications (1)

Application Number Title Priority Date Filing Date
EP85400072A Expired EP0149578B1 (fr) 1984-01-17 1985-01-16 Nouveaux dérivés de la xanthine, leur procédé de préparation et les compositions pharmaceutiques les renfermant

Country Status (15)

Country Link
US (1) US4599338A (xx)
EP (1) EP0149578B1 (xx)
JP (1) JPS60174788A (xx)
AT (1) ATE40368T1 (xx)
AU (1) AU569983B2 (xx)
CA (1) CA1228353A (xx)
DE (1) DE3567870D1 (xx)
ES (1) ES8605806A1 (xx)
FR (1) FR2558162B1 (xx)
GR (1) GR850126B (xx)
IE (1) IE57713B1 (xx)
NZ (1) NZ210846A (xx)
OA (1) OA07934A (xx)
PT (1) PT79834B (xx)
ZA (1) ZA85388B (xx)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105001222A (zh) * 2002-08-21 2015-10-28 勃林格殷格翰制药两合公司 8-[3-氨基-哌啶-1-基]-黄嘌呤化合物，其制备方法及作为药物制剂的用途

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772607A (en) * 1986-05-20 1988-09-20 Warner-Lambert Company Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US4755517A (en) * 1986-07-31 1988-07-05 Warner-Lambert Company Derivatives of xanthine, pharmaceutical compositions and methods of use therefor
GB8716313D0 (en) * 1987-07-10 1987-08-19 Janssen Pharmaceutica Nv 2-(heterocyclylalkyl)imidazopyridines
FR2665636B1 (fr) * 1990-08-10 1994-10-07 Adir Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer.
DE69229257D1 (de) * 1991-11-08 1999-07-01 Kyowa Hakko Kogyo Kk Xanthinderivate zur Behandlung der Demenz
US6469017B1 (en) * 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
EP0952826B1 (en) * 1997-01-17 2001-11-14 Takeda Chemical Industries, Ltd. Idebenone containing combination agent for treating alzheimer's disease
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
US7019136B2 (en) * 2000-04-07 2006-03-28 Novartis, Ag 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
US6919337B2 (en) * 2000-04-07 2005-07-19 Novartis, Ag 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
GB0008694D0 (en) * 2000-04-07 2000-05-31 Novartis Ag Organic compounds
AU2002234640B8 (en) * 2001-02-24 2009-11-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivative, production and use thereof as a medicament
DE10238243A1 (de) * 2002-08-21 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CA2554426C (en) * 2004-01-28 2012-10-16 Kyowa Hakko Kogyo Co., Ltd. Agents for treating migraine
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en) * 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) * 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de) * 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
JPWO2006004201A1 (ja) * 2004-07-01 2008-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経再生促進剤
DE102004043944A1 (de) 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) * 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
JP5323684B2 (ja) * 2006-05-04 2013-10-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 多形体
US8071583B2 (en) 2006-08-08 2011-12-06 Boehringer Ingelheim International Gmbh Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus
JP5769966B2 (ja) * 2007-08-17 2015-08-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｆａｂ関連疾患治療用プリン誘導体
JP5603248B2 (ja) * 2007-12-21 2014-10-08 エンダセア， インコーポレイテッド Ａ１アデノシン受容体アンタゴニスト
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
EP2326326B1 (en) * 2008-08-15 2019-10-09 Boehringer Ingelheim International GmbH Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
PL2731947T3 (pl) 2011-07-15 2019-07-31 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
WO2016086008A1 (en) * 2014-11-26 2016-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Small molecule aldehyde dehydrogenase inhibitors and methods of use thereof
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1133989A (en) * 1964-12-08 1968-11-20 Chugai Pharmaceutical Co Ltd Theophylline derivatives, their salts and process for preparing the same
FR2116302A1 (en) * 1970-12-07 1972-07-13 Brun Lab Sa Le 8-aminotheophyllines - with coronary - vasodilator bronchodilator diuretic, spasmolytic, antiinflammatory and analgesic activity
NO154582C (no) * 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
DE2922159A1 (de) * 1979-05-31 1980-12-04 Boehringer Mannheim Gmbh Neue xanthin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
CH648559A5 (de) * 1981-07-20 1985-03-29 Siegfried Ag Theophyllinderivate und verfahren zu deren herstellung.
FR2531085A1 (fr) * 1982-07-28 1984-02-03 Adir Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105001222A (zh) * 2002-08-21 2015-10-28 勃林格殷格翰制药两合公司 8-[3-氨基-哌啶-1-基]-黄嘌呤化合物，其制备方法及作为药物制剂的用途
CN105001222B (zh) * 2002-08-21 2017-11-07 勃林格殷格翰制药两合公司 8‑[3‑氨基‑哌啶‑1‑基]‑黄嘌呤化合物，其制备方法及作为药物制剂的用途

Also Published As

Publication number Publication date
CA1228353A (fr) 1987-10-20
ZA85388B (en) 1985-08-28
JPS60174788A (ja) 1985-09-09
EP0149578A2 (fr) 1985-07-24
ES539658A0 (es) 1986-04-01
DE3567870D1 (en) 1989-03-02
GR850126B (xx) 1985-05-16
ES8605806A1 (es) 1986-04-01
FR2558162B1 (fr) 1986-04-25
IE850103L (en) 1985-07-17
US4599338A (en) 1986-07-08
PT79834B (fr) 1986-12-18
JPH0415792B2 (xx) 1992-03-19
OA07934A (fr) 1987-01-31
PT79834A (fr) 1985-02-01
ATE40368T1 (de) 1989-02-15
IE57713B1 (en) 1993-03-10
AU3775685A (en) 1985-07-25
NZ210846A (en) 1988-01-08
FR2558162A1 (fr) 1985-07-19
AU569983B2 (en) 1988-02-25
EP0149578A3 (en) 1985-09-18

Similar Documents

Publication Publication Date Title
EP0149578B1 (fr) Nouveaux dérivés de la xanthine, leur procédé de préparation et les compositions pharmaceutiques les renfermant
EP0515240B1 (fr) Composés N-(aminoalkyl)pipéridine et leurs énantiomères comme antagonistes des récepteurs des neurokinines, procédés pour leur préparation et compositions pharmaceutiques les contenant
EP0202164B1 (fr) Dérivés de (benzoyl-4 pipéridino)-2 phenyl-1 alcanols, leur préparation et leur application en thérapeutique
CA1207766A (fr) Procede de preparation de nouveaux derives de la xanthine
EP0307303B1 (fr) [(Pyrimidinyl-2)-aminoalkyl]-1 pipéridines, leur préparation et leur application en thérapeutique
WO1998029409A1 (fr) Sels d'addition acides de compose de piperidine optiquement actif et procede de production associe
EP0377528B1 (fr) Pipéridines, procédés de préparation et médicaments les contenant
EP0005689B1 (fr) Nouveaux acides lactame-N-acétiques et leurs amides, leurs procédés de préparation et compositions thérapeutiques
EP0090733B1 (fr) Polyméthylènes-imines disubstituées, leurs procédés de préparation et les compositions pharmaceutiques les renfermant
EP1960387B1 (fr) Derives de isoquinoline et benzo[h]isoquinoline, leur preparation et leur utilisation en therapeutique en tant qu antagonistes du recepteur de l histamine h3
EP0004494B1 (fr) Nouveaux dérivés de 1,3-dihydro 3-(1-(2-(2,3-dihydro 1,4-benzo-dioxin-2-yl)2-hydroxy éthyl)pipéridin-4-yl)2H-indol 2-one, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant
EP0092479B1 (fr) Polymethylène diamines, n,n'-substituées, leurs procédés de préparation et les compositions pharmaceutiques les renfermant
FR2672213A1 (fr) Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
EP0301936B1 (fr) Dérivés de pipéridine, leur préparation et leur application en thérapeutique
EP0613898A1 (fr) Nouveaux composés (aryl(alkyl)carbonyl)-hétérocycliques leurs procédés de préparation et les compositions qui les contiennent
CA1117944A (fr) Procedes de preparation de nouvelles piperazines disubstituees
FR2753970A1 (fr) Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique
EP2313384B1 (fr) Phenyl-alkyl piperazines ayant une activite modulatrice du tnf
EP0292400B1 (fr) Dérivés du Spiro (4,5) décane, leur procédé de préparation et les compositons pharmaceutiques les renfermant
EP0647639A1 (fr) Hétéroarylpipéridines, procédé pour leur préparation et compositions pharmaceutiques les contenant
EP0008259A1 (fr) Nouveaux dérivés de la pipéridylbenzimidazolinone, leurs procédés de préparation et les compositions pharmaceutiques les renfermant
EP0122855B1 (fr) Piperidines disubstitutées, leurs procédés de préparation et les compositions pharmaceutiques les renfermant
EP0005091B1 (fr) Nouvelles pipérazines monosubstituées, leurs procédés de préparation et les compositions pharmaceutiques les renfermant
JPH11506470A (ja) 新規複素環式化合物
CA2359572A1 (fr) 1-(piperidin-4-yl)-3-(aryl)-isothiourees substituees, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

17P Request for examination filed

Effective date: 19850121

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19880111

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 40368

Country of ref document: AT

Date of ref document: 19890215

Kind code of ref document: T

ITF It: translation for a ep patent filed

Owner name: SOCIETA' ITALIANA BREVETTI S.P.A.

REF Corresponds to:

Ref document number: 3567870

Country of ref document: DE

Date of ref document: 19890302

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
EPTA Lu: last paid annual fee
EAL Se: european patent in force in sweden

Ref document number: 85400072.6

ITTA It: last paid annual fee
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20001120

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20001124

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20001204

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20001228

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20010110

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20010119

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20010123

Year of fee payment: 17

Ref country code: FR

Payment date: 20010123

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20010124

Year of fee payment: 17

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020116

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020116

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020117

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020131

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020131

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020131

BERE Be: lapsed

Effective date: 20020131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020801

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020801

EUG Se: european patent has lapsed

Ref document number: 85400072.6

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20020116

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020930

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20020801

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST